Loading
No insider purchase over the last 90 days. The latest was filed 12 Jun 2026.
Sirio Pharma Co., Ltd.: what insiders have been doing
This page follows insider dealings at Sirio Pharma Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Food & Beverage sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Sirio Pharma Co., Ltd. logged 1 filing by 1 insider.
Every open-market trade in the period is a purchase: 1 purchase worth €13k, from 1 insider, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The largest single trade was a purchase of €13k by 刘若阳, published on 12 June 2026. Those buying include 1 chief executive.
Compared with its exchange (533 companies, median 2 filings), a count of 1 filing is below the norm. The full history, which starts in 2021, counts 4 purchases against 2 sales.
The clock since the last published purchase (12 June 2026) now reads 128 days.
Other companies in the same sector with recent insider buying flagged by our signals: Village Farms International, Inc. and Orkla ASA. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.
Insider Decl.
6
Thresholds
n/a
Buy Volume
€458,721
4 ops. · all time
Sell Volume
€6M
2 ops. · all time
Who traded when
BuySale刘若阳1 buy
郑丽群1 buy
陈琼1 sale
Since the insiders bought
- +1.5%Entry CN¥17.13 · Close at T+90 CN¥17.38
- -7.5%Entry CN¥25.00 · Close at T+90 CN¥23.13
- +25.6%Entry CN¥18.80 · Close at T+365 CN¥23.62
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,158 of 24,161 companies
37.5
score / 100
Value40
Quality35
FCF yld2.3%
Earn yld2.4%
EV/EBITDA20.6x
ROE0.9%
Gross mgn31%
Net mgn3.2%
Debt/EBITDA4.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥18.27
Analyst consensus
1 analysts1.67/5
CN¥23.00Target CN¥23.00(+26%)CN¥23.00
Income statement
RevenueCN¥4.3B
Gross profitCN¥1.3B31% margin
EBITDACN¥354.6M8% margin
Net incomeCN¥136.5M3.0% margin
Valuation
PER (trailing)42.5x
P/Book1.8x
Beta0.32
Balance sheet & cash
Market capCN¥5.6B
Total debtCN¥1.7B
Free Cash FlowCN¥128.9M
Debt / Equity61%
Profitability & ownership
ROE0.9%
ROA2.5%
% insiders66.2%
% institutions10.1%
Last declaration on 12 June 2026
Declarations6 total
6 of 6 declarations
About Sirio Pharma Co., Ltd.
仙乐健康 is a company focused on the agro-food sector, providing health and nutrition products. It is listed on the XSHE market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations